Cargando…

Globally Rare BRCA2 Variants With Founder Haplotypes in the South African Population: Implications for Point-of-Care Testing Based on a Single-Institution BRCA1/2 Next-Generation Sequencing Study

Breast cancer patients historically benefitted from population-based genetic research performed in South Africa, which led to the development of founder-based BRCA1/2 diagnostic tests. With the advent of next-generation sequencing (NGS) technologies, the clinical utility of limited, targeted genetic...

Descripción completa

Detalles Bibliográficos
Autores principales: Oosthuizen, Jaco, Kotze, Maritha J., Van Der Merwe, Nicole, Myburgh, Ettienne J., Bester, Phillip, van der Merwe, Nerina C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7908826/
https://www.ncbi.nlm.nih.gov/pubmed/33643918
http://dx.doi.org/10.3389/fonc.2020.619469
_version_ 1783655795389366272
author Oosthuizen, Jaco
Kotze, Maritha J.
Van Der Merwe, Nicole
Myburgh, Ettienne J.
Bester, Phillip
van der Merwe, Nerina C.
author_facet Oosthuizen, Jaco
Kotze, Maritha J.
Van Der Merwe, Nicole
Myburgh, Ettienne J.
Bester, Phillip
van der Merwe, Nerina C.
author_sort Oosthuizen, Jaco
collection PubMed
description Breast cancer patients historically benefitted from population-based genetic research performed in South Africa, which led to the development of founder-based BRCA1/2 diagnostic tests. With the advent of next-generation sequencing (NGS) technologies, the clinical utility of limited, targeted genetic assays were questioned. The study focused on mining NGS data obtained from an extensive single-institution NGS series (n=763). The aims were to determine (i) the prevalence of the most common recurrent/founder variants in patients referred for NGS directly; and (ii) to explore the data for inferred haplotypes associated with previous and potential new recurrent/founder variants. The identification of additional founder variants was essential for promoting and potentially advancing to rapid founder-based BRCA1/2 point-of-care (POC) technology as a time- and cost-effective alternative. NGS revealed actionable BRCA1/2 variants in 11.1% of patients tested (BRCA1 – 4.7%; BRCA2 – 6.4%), of which 22.4% represented variants currently screened for using first-tier targeted genetic testing. A retrospective investigation into the overall mutation-positive rate for an extended cohort (n=1906), which included first-tier test results, revealed that targeted genetic testing identified 74% of all pathogenic variants. This percentage justified the use of targeted genetic testing as a first-tier assay. Inferred haplotype analysis confirmed the founder status of BRCA2 c.5771_5774del (rs80359535) and c.7934del (rs80359688) and revealed an additional African founder variant (BRCA2 c.582G>A – rs80358810). A risk-benefit analysis using a questionnaire-based survey was performed in parallel to determine genetic professionals’ views regarding POC testing. This was done to bridge the clinical implementation gap between haplotype analysis and POC testing as a first-tier screen during risk stratification of breast and ovarian cancer patients. The results reflected high acceptance (94%) of BRCA1/2 POC testing when accompanied by genetic counselling. Establishing the founder status for several recurrent BRCA2 variants across ethnic groups supports unselected use of the BRCA POC assay in all SA breast/ovarian cancer patients by recent local and international public health recommendations. Incorporating POC genotyping into the planned NGS screening algorithm of the Department of Health will ensure optimal use of the country’s recourses to adhere to the set standards for optimal care and management for all breast cancer patients.
format Online
Article
Text
id pubmed-7908826
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-79088262021-02-27 Globally Rare BRCA2 Variants With Founder Haplotypes in the South African Population: Implications for Point-of-Care Testing Based on a Single-Institution BRCA1/2 Next-Generation Sequencing Study Oosthuizen, Jaco Kotze, Maritha J. Van Der Merwe, Nicole Myburgh, Ettienne J. Bester, Phillip van der Merwe, Nerina C. Front Oncol Oncology Breast cancer patients historically benefitted from population-based genetic research performed in South Africa, which led to the development of founder-based BRCA1/2 diagnostic tests. With the advent of next-generation sequencing (NGS) technologies, the clinical utility of limited, targeted genetic assays were questioned. The study focused on mining NGS data obtained from an extensive single-institution NGS series (n=763). The aims were to determine (i) the prevalence of the most common recurrent/founder variants in patients referred for NGS directly; and (ii) to explore the data for inferred haplotypes associated with previous and potential new recurrent/founder variants. The identification of additional founder variants was essential for promoting and potentially advancing to rapid founder-based BRCA1/2 point-of-care (POC) technology as a time- and cost-effective alternative. NGS revealed actionable BRCA1/2 variants in 11.1% of patients tested (BRCA1 – 4.7%; BRCA2 – 6.4%), of which 22.4% represented variants currently screened for using first-tier targeted genetic testing. A retrospective investigation into the overall mutation-positive rate for an extended cohort (n=1906), which included first-tier test results, revealed that targeted genetic testing identified 74% of all pathogenic variants. This percentage justified the use of targeted genetic testing as a first-tier assay. Inferred haplotype analysis confirmed the founder status of BRCA2 c.5771_5774del (rs80359535) and c.7934del (rs80359688) and revealed an additional African founder variant (BRCA2 c.582G>A – rs80358810). A risk-benefit analysis using a questionnaire-based survey was performed in parallel to determine genetic professionals’ views regarding POC testing. This was done to bridge the clinical implementation gap between haplotype analysis and POC testing as a first-tier screen during risk stratification of breast and ovarian cancer patients. The results reflected high acceptance (94%) of BRCA1/2 POC testing when accompanied by genetic counselling. Establishing the founder status for several recurrent BRCA2 variants across ethnic groups supports unselected use of the BRCA POC assay in all SA breast/ovarian cancer patients by recent local and international public health recommendations. Incorporating POC genotyping into the planned NGS screening algorithm of the Department of Health will ensure optimal use of the country’s recourses to adhere to the set standards for optimal care and management for all breast cancer patients. Frontiers Media S.A. 2021-02-12 /pmc/articles/PMC7908826/ /pubmed/33643918 http://dx.doi.org/10.3389/fonc.2020.619469 Text en Copyright © 2021 Oosthuizen, Kotze, Van Der Merwe, Myburgh, Bester and van der Merwe http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Oosthuizen, Jaco
Kotze, Maritha J.
Van Der Merwe, Nicole
Myburgh, Ettienne J.
Bester, Phillip
van der Merwe, Nerina C.
Globally Rare BRCA2 Variants With Founder Haplotypes in the South African Population: Implications for Point-of-Care Testing Based on a Single-Institution BRCA1/2 Next-Generation Sequencing Study
title Globally Rare BRCA2 Variants With Founder Haplotypes in the South African Population: Implications for Point-of-Care Testing Based on a Single-Institution BRCA1/2 Next-Generation Sequencing Study
title_full Globally Rare BRCA2 Variants With Founder Haplotypes in the South African Population: Implications for Point-of-Care Testing Based on a Single-Institution BRCA1/2 Next-Generation Sequencing Study
title_fullStr Globally Rare BRCA2 Variants With Founder Haplotypes in the South African Population: Implications for Point-of-Care Testing Based on a Single-Institution BRCA1/2 Next-Generation Sequencing Study
title_full_unstemmed Globally Rare BRCA2 Variants With Founder Haplotypes in the South African Population: Implications for Point-of-Care Testing Based on a Single-Institution BRCA1/2 Next-Generation Sequencing Study
title_short Globally Rare BRCA2 Variants With Founder Haplotypes in the South African Population: Implications for Point-of-Care Testing Based on a Single-Institution BRCA1/2 Next-Generation Sequencing Study
title_sort globally rare brca2 variants with founder haplotypes in the south african population: implications for point-of-care testing based on a single-institution brca1/2 next-generation sequencing study
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7908826/
https://www.ncbi.nlm.nih.gov/pubmed/33643918
http://dx.doi.org/10.3389/fonc.2020.619469
work_keys_str_mv AT oosthuizenjaco globallyrarebrca2variantswithfounderhaplotypesinthesouthafricanpopulationimplicationsforpointofcaretestingbasedonasingleinstitutionbrca12nextgenerationsequencingstudy
AT kotzemarithaj globallyrarebrca2variantswithfounderhaplotypesinthesouthafricanpopulationimplicationsforpointofcaretestingbasedonasingleinstitutionbrca12nextgenerationsequencingstudy
AT vandermerwenicole globallyrarebrca2variantswithfounderhaplotypesinthesouthafricanpopulationimplicationsforpointofcaretestingbasedonasingleinstitutionbrca12nextgenerationsequencingstudy
AT myburghettiennej globallyrarebrca2variantswithfounderhaplotypesinthesouthafricanpopulationimplicationsforpointofcaretestingbasedonasingleinstitutionbrca12nextgenerationsequencingstudy
AT besterphillip globallyrarebrca2variantswithfounderhaplotypesinthesouthafricanpopulationimplicationsforpointofcaretestingbasedonasingleinstitutionbrca12nextgenerationsequencingstudy
AT vandermerwenerinac globallyrarebrca2variantswithfounderhaplotypesinthesouthafricanpopulationimplicationsforpointofcaretestingbasedonasingleinstitutionbrca12nextgenerationsequencingstudy